| 0.568 -0.017 (-2.91%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.86  |
1-year : | 1 |
| Resists | First : | 0.74 |
Second : | 0.86 |
| Pivot price | 0.66 |
|||
| Supports | First : | 0.55 |
Second : | 0.45 |
| MAs | MA(5) : | 0.59 |
MA(20) : | 0.68 |
| MA(100) : | 1.12 |
MA(250) : | 2.11 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.9 |
D(3) : | 9.3 |
| RSI | RSI(14): 16.1 |
|||
| 52-week | High : | 5.09 | Low : | 0.55 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ APTO ] has closed above bottom band by 6.2%. Bollinger Bands are 22.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.6 - 0.61 | 0.61 - 0.61 |
| Low: | 0.54 - 0.55 | 0.55 - 0.55 |
| Close: | 0.56 - 0.57 | 0.57 - 0.58 |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Fri, 26 Jul 2024
Aptose Biosciences Inc. (NASDAQ:APTO) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Thu, 25 Jul 2024
Aptose Biosciences hits 52-week low, trading at 0.5899 USD - Investing.com
Wed, 24 Jul 2024
StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Fri, 19 Jul 2024
Aptose Biosciences receives Nasdaq compliance warning - Investing.com
Fri, 19 Jul 2024
Aptose Announces Receipt of Deficiency Notice from Nasdaq - GlobeNewswire
Fri, 19 Jul 2024
Aptose Announces Receipt of Deficiency Notice from Nasdaq - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 18 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 17.1 (%) |
| Held by Institutions | 5.8 (%) |
| Shares Short | 93 (K) |
| Shares Short P.Month | 77 (K) |
| EPS | -6.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -115.2 % |
| Return on Equity (ttm) | -361.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | 56.8 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|